Management of Ductal Carcinoma In Situ of the Breast: A Review.
暂无分享,去创建一个
F. Vicini | C. Shah | D. Wazer | D. Arthur | Frank Vicini | Jessica Wobb | Douglas Arthur | Chirag Shah | Bindu Manyam | Neilendu Kundu | David Wazer | Eduardo Fernandez | J. Wobb | B. Manyam | E. Fernández | N. Kundu
[1] Richard J. K. Taylor,et al. Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis , 2015, BMC Cancer.
[2] Barbara L. Smith,et al. Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS) , 2013, Breast Cancer Research and Treatment.
[3] N. Rodríguez,et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. , 2013, International journal of radiation oncology, biology, physics.
[4] B. E. F. Isher,et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. , 2002 .
[5] F. Vicini,et al. Use of intensity modulated radiation therapy to reduce acute and chronic toxicities of breast cancer patients treated with traditional and accelerated whole breast irradiation. , 2012, Practical radiation oncology.
[6] R. Peto,et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. , 2010, Journal of the National Cancer Institute. Monographs.
[7] Stephen W Duffy,et al. Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study , 2016, The Lancet. Oncology.
[8] A. Luini,et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. , 2013, The Lancet. Oncology.
[9] T. Major,et al. Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[10] F. Vicini,et al. Twenty-Year Outcomes after Breast-Conserving Surgery and Definitive Radiotherapy for Mammographically Detected Ductal Carcinoma In Situ , 2012, Annals of Surgical Oncology.
[11] A. Ocaña,et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. , 2011, Journal of the National Cancer Institute.
[12] F. Vicini,et al. Ductal Carcinoma in Situ of the Breast Treated with Accelerated Partial Breast Irradiation Using Balloon-Based Brachytherapy , 2010, Annals of Surgical Oncology.
[13] S. Stanley Young,et al. Deming, data and observational studies , 2011 .
[14] E. Rakovitch,et al. Long-term outcomes of hypofractionation versus conventional radiation therapy after breast-conserving surgery for ductal carcinoma in situ of the breast. , 2014, International journal of radiation oncology, biology, physics.
[15] Peter Y. Chen,et al. Outcomes of Breast Cancer Patients Treated with Accelerated Partial Breast Irradiation Via Multicatheter Interstitial Brachytherapy: The Pooled Registry of Multicatheter Interstitial Sites (PROMIS) Experience , 2015, Annals of Surgical Oncology.
[16] T. Julian,et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial , 2016, The Lancet.
[17] L. Esserman,et al. Oncoplastic Mammoplasty as a Strategy for Reducing Reconstructive Complications Associated with Postmastectomy Radiation Therapy , 2014, The breast journal.
[18] M. Amichetti,et al. Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. , 2006, The Lancet. Oncology.
[19] L. Livi,et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. , 2015, European journal of cancer.
[20] H. Bartelink,et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Richard Pötter,et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial , 2016, The Lancet.
[22] T. Julian,et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. , 2011, Journal of the National Cancer Institute.
[23] Ping Sun,et al. Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ. , 2015, JAMA oncology.
[24] L. Holmberg,et al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] S. Shak,et al. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone , 2015, Breast Cancer Research and Treatment.
[26] Benjamin D. Smith,et al. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. , 2011, International journal of radiation oncology, biology, physics.
[27] L. Esserman,et al. Rethinking the Standard for Ductal Carcinoma In Situ Treatment. , 2015, JAMA oncology.
[28] Umberto Veronesi,et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. , 2002, The New England journal of medicine.
[29] L. Esserman,et al. Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ. , 2011, Breast.
[30] E. van Limbergen,et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. , 2015, The Lancet. Oncology.
[31] F. Vicini,et al. Should Ductal Carcinoma-in-situ (DCIS) Be Removed from the ASTRO Consensus Panel Cautionary Group for Off-protocol Use of Accelerated Partial Breast Irradiation (APBI)? A Pooled Analysis of Outcomes for 300 Patients with DCIS Treated with APBI , 2013, Annals of Surgical Oncology.
[32] Anthony Fyles,et al. Long-term results of hypofractionated radiation therapy for breast cancer. , 2010, The New England journal of medicine.
[33] A. Jemal,et al. Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.
[34] Joanne S Haviland,et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. , 2013, The Lancet. Oncology.
[35] F. Vicini,et al. Defining the clinical target volume for patients with early-stage breast cancer treated with lumpectomy and accelerated partial breast irradiation: a pathologic analysis. , 2004, International journal of radiation oncology, biology, physics.
[36] Rakesh R. Patel,et al. The American Brachytherapy Society consensus statement for accelerated partial-breast irradiation. , 2013, Brachytherapy.
[37] B. McCormick. RTOG 9804: A prospective randomized trial for "good risk" ductal carcinoma in situ (DCIS), comparing radiation (RT) to observation (OBS) , 2012 .
[38] W. Barry,et al. Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] F. Vicini,et al. Long-term outcome in patients with ductal carcinoma in situ treated with breast-conserving therapy: implications for optimal follow-up strategies. , 2012, International journal of radiation oncology, biology, physics.
[40] D. Holmes,et al. Targeted Intraoperative Radiotherapy for the Management of Ductal Carcinoma In Situ of the Breast , 2016, The breast journal.
[41] S. Spear,et al. Nipple-Sparing Mastectomy , 2009, Plastic and reconstructive surgery.
[42] R. Gray,et al. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] George W. Sledge,et al. A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast , 2013, Journal of the National Cancer Institute.
[44] H. Bartelink,et al. Long‐term outcome after breast‐conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast , 2005, Cancer.
[45] C. Aydın,et al. Oncoplastic reduction mammoplasty for breast cancer in women with macromastia: Oncological long-term outcomes. , 2017, Asian journal of surgery.
[46] J. Cuzick,et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial , 2010, The Lancet. Oncology.
[47] S. Wheeler,et al. Racial/Ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review. , 2015, American journal of public health.
[48] F. Vicini,et al. Clinical outcomes using accelerated partial breast irradiation in patients with ductal carcinoma in situ. , 2012, Clinical breast cancer.
[49] M. Rendi,et al. Adjuvant Endocrine Therapy in Patients with Ductal Carcinoma In Situ: A Population-Based Retrospective Analysis from 2005 to 2012 in the National Cancer Data Base , 2015, Annals of Surgical Oncology.
[50] L. Esserman,et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial , 2014, The Lancet.